rilpivirine

(redirected from Edurant)
Also found in: Medical.
Related to Edurant: Emtriva, Intelence
Translations

rilpivirine

n rilpivirina
References in periodicals archive ?
According to the company, JULUCA is a once-daily, antiretroviral combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) marketed as TIVICAY, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed as EDURANT for human immunodeficiency virus type 1 (HIV-1) infection.
Rilpivirine is already approved as Edurant, a once-daily 25-mg tablet for oral therapy.
1) Viral load control rates did not differ significantly in people taking a combination including a nonnucleoside (like Edurant, Intelence, or Sustiva) if their pill-taking on-time record lay between 90% and 94% or at 95% or greater.
htm (last visited June 3, 2013) (listing a number of HIV drugs approved after January 1, 2005, including Edurant, extended-release Viramune XR, and combination drug Stribild.
J&J's subsidiary Tibotec Pharmaceuticals will sell the one-pill-a-day drug under the name Edurant.
Co-administration with other products Complera should not be administered concurrently with other medicinal products containing any of the same active components, emtricitabine, rilpivirine, or tenofovir disoproxil fumarate (Emtriva, Edurant, Viread, Truvada, Atripla), with medicinal products containing lamivudine (Epivir, Epivir-HBV, Epzicom, Combivir, Trizivir), or with adefovir dipivoxil (Hepsera).
Juluca is a once-daily, antiretroviral combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) marketed by ViiV Healthcare as Tivicay, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by Janssen as Edurant.
ViiV Healthcare's Tivicay is a dolutegravir, while Janssen Sciences Ireland UC's Edurant is a rilpivirine.
Contract award notice: 54/S/16/SU/GE/N/0038 Suministro de productos farmacuticos (CAELYX, EDURANT, ZITIGA), para el Complejo Hospitalario Universitario Insular Materno infantil de Gran Canaria.
The marketing authorization for Odefsey is supported by a bioequivalence study demonstrating that Odefsey achieved similar drug levels of emtricitabine and TAF in the blood as Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg; E/C/F/TAF) and similar drug levels of rilpivirine as Edurant (rilpivirine 25 mg).
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor and is presently being marketed as Edurant, while dolutegravir is an integrase inhibitor marketed as Tivicay.